Gilead Sciences Files 8-K on Financials

TL;DR

GILD dropped an 8-K on Feb 11th detailing financial results. Check it out.

AI Summary

On February 11, 2025, Gilead Sciences, Inc. filed an 8-K report to disclose information regarding its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial performance. Gilead Sciences, Inc. is incorporated in Delaware and headquartered in Foster City, California.

Why It Matters

This 8-K filing provides investors with crucial updates on Gilead Sciences' financial health and operational results, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial disclosure filing and does not indicate any immediate or significant risks.

Key Players & Entities

• GILEAD SCIENCES, INC. (company) — Registrant
• February 11, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Foster City, California (location) — Principal Executive Offices
• 650 - 574-3000 (phone_number) — Registrant's Telephone Number

FAQ

From the Filing

0000882095-25-000003.txt : 20250211 0000882095-25-000003.hdr.sgml : 20250211 20250211160428 ACCESSION NUMBER: 0000882095-25-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250211 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250211 DATE AS OF CHANGE: 20250211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 25609727 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 gild-20250211.htm FORM 8-K gild-20250211 0000882095 false 0000882095 2025-02-11 2025-02-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 11, 2025 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.) 333 Lakeside Drive , Foster City , California (Address of principal executive offices) 94404 (Zip Code) 650 - 574-3000 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Section 2 - FINANCIAL INFORMATION Item 2.02      Results of Operations and Financial Condition. On February 11, 2025 , Gilead Sciences, Inc., a Delaware corporation (“Gilead”), issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAA